{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:29:27Z","timestamp":1791289767945,"version":"4.3.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Institute of Health and Biomedical Research of Alicante (ISABIAL)\/FISABIO Foundation","award":["180140"],"award-info":[{"award-number":["180140"]}]},{"name":"Innovation Prize in the Health Field of Celgene of the University of Alcal\u00e1 de Henares"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Psoriasis and non-alcoholic fatty liver disease (NAFLD) are both inflammatory diseases. The study objective was to estimate the risk of NAFLD, non-alcoholic steatohepatitis, and liver fibrosis (by liver stiffness and liver biopsy) in patients with psoriasis and to determine the epidemiological, clinical, immunological (TNF-\u03b1, IL-2, IL-6, IL-12, IL-17, IL-23, and TGF-\u03b2) characteristics, and bacterial translocation. Of the 215 psoriatic patients included, 91 presented NAFLD (prevalence: 42.3%). Compared to patients with psoriasis alone, those with NAFLD were significantly more likely to have metabolic syndrome, diabetes, dyslipidemia, body mass index\u2009\u2265\u200930\u00a0kg\/m<jats:sup>2<\/jats:sup>, homeostatic model assessment of insulin resistance\u2009\u2265\u20092.15, and greater psoriasis area severity index. NAFLD patients also had significantly higher levels of TNF-\u03b1 (p\u2009=\u20090.002) and TGF-\u03b2 (p\u2009=\u20090.007) and a higher prevalence of bacterial translocation (29.7% vs. 13.7%; p\u2009=\u20090.004). Liver stiffness measurement was over 7.8\u00a0kPa in 17.2% (15\/87) of NAFLD patients; 13 of these underwent liver biopsy, and 5.7% (5\/87) had liver fibrosis, while 1.1% (1\/87) had advanced fibrosis or non-alcoholic steatohepatitis. In conclusion the prevalence of NAFLD in patients with psoriasis is high and associated with a higher prevalence of metabolic syndrome features, bacterial translocation and a higher pro-inflammatory state. It is worth mentioning that liver fibrosis and non-alcoholic steatohepatitis are not frequent in this population of patients.<\/jats:p>","DOI":"10.1038\/s41598-021-88043-8","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T10:19:00Z","timestamp":1619000340000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6007-7320","authenticated-orcid":false,"given":"Isabel","family":"Belinch\u00f3n-Romero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8307-1813","authenticated-orcid":false,"given":"Pablo","family":"Bellot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1875-6722","authenticated-orcid":false,"given":"David","family":"Romero-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4950-3189","authenticated-orcid":false,"given":"Isolina","family":"Herraiz-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5113-3637","authenticated-orcid":false,"given":"Francisco","family":"Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5105-1201","authenticated-orcid":false,"given":"Rub\u00e9n","family":"Frances","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6501-9867","authenticated-orcid":false,"given":"Jos\u00e9-Manuel","family":"Ramos-Rinc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"key":"88043_CR1","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1111\/jdv.15177","volume":"32","author":"E Dauden","year":"2018","unstructured":"Dauden, E. et al. Position statement for the management of comorbidities in psoriasis. J. Eur. Acad. Dermatol. Venereol. 32, 2058\u20132073 (2018).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"88043_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/ijms17020217","volume":"17","author":"A Mantovani","year":"2016","unstructured":"Mantovani, A., Gisondi, P., Lonardo, A. & Targher, G. Relationship between non-alcoholic fatty liver disease and psoriasis: A novel Hepato-Dermal axis?. Int. J. Mol. Sci. 17, 217 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"88043_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"370","author":"CE Griffiths","year":"2007","unstructured":"Griffiths, C. E. & Barker, J. N. Pathogenesis and clinical features of psoriasis. Lancet 370, 263\u2013271 (2007).","journal-title":"Lancet"},{"key":"88043_CR4","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ad.2013.12.008","volume":"105","author":"C Ferr\u00e1ndiz","year":"2014","unstructured":"Ferr\u00e1ndiz, C., Carrascosa, J. M. & Toro, M. Prevalencia de la psoriasis en Espa\u00f1a en la era de los agentes biol\u00f3gicos. Actas Dermosifiliogr. 105, 504\u2013509 (2014).","journal-title":"Actas Dermosifiliogr."},{"key":"88043_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","volume":"76","author":"J Takeshita","year":"2017","unstructured":"Takeshita, J. et al. Psoriasis and comorbid diseases: Epidemiology. J. Am. Acad. Dermatol. 76, 377\u2013390 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"88043_CR6","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jhep.2009.04.020","volume":"51","author":"P Gisondi","year":"2009","unstructured":"Gisondi, P., Targher, G., Zoppini, G. & Girolomoni, G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J. Hepatol. 51, 758\u2013764 (2009).","journal-title":"J. Hepatol."},{"key":"88043_CR7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/ced.12672","volume":"40","author":"R Abedini","year":"2015","unstructured":"Abedini, R., Salehi, M., Lajevardi, V. & Beygi, S. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin. Exp. Dermatol. 40, 722\u2013727 (2015).","journal-title":"Clin. Exp. Dermatol."},{"key":"88043_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1468-3083.2010.03841.x","volume":"25","author":"KS Wenk","year":"2011","unstructured":"Wenk, K. S., Arrington, K. C. & Ehrlich, A. Psoriasis and non-alcoholic fatty liver disease. J. Eur. Acad. Dermatol. Venereol. 25, 383\u2013391 (2011).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"88043_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3109\/07853890.2010.518623","volume":"43","author":"G Musso","year":"2011","unstructured":"Musso, G., Gambino, R., Cassader, M. & Pagano, G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med. 43, 617\u2013649 (2011).","journal-title":"Ann. Med."},{"key":"88043_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi, Z. et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11\u201320 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"88043_CR11","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.jhep.2016.07.033","volume":"65","author":"R Pais","year":"2016","unstructured":"Pais, R. et al. NAFLD and liver transplantation: Current burden and expected challenges. J. Hepatol. 65, 1245\u20131257 (2016).","journal-title":"J. Hepatol."},{"key":"88043_CR12","first-page":"33","volume":"11","author":"O Awosika","year":"2018","unstructured":"Awosika, O. et al. A case-control study to evaluate the prevalence of nonalcoholic fatty liver disease among patients with moderate-to-severe psoriasis. J. Clin. Aesthet. Dermatol. 11, 33\u201337 (2018).","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"88043_CR13","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jaad.2008.10.062","volume":"60","author":"M Icen","year":"2009","unstructured":"Icen, M. et al. Trends in incidence of adult-onset psoriasis over three decades: A population-based study. J. Am. Acad. Dermatol. 60, 394\u2013401 (2009).","journal-title":"J. Am. Acad. Dermatol."},{"key":"88043_CR14","doi-asserted-by":"publisher","first-page":"e352","DOI":"10.1111\/ajd.13015","volume":"60","author":"K Phan","year":"2019","unstructured":"Phan, K., Onggo, J., Charlton, O. & Smith, S. D. Relationship between psoriasis and non-alcoholic fatty liver disease: Updated systematic review and adjusted meta-analysis. Australas. J. Dermatol. 60, e352\u2013e355 (2019).","journal-title":"Australas. J. Dermatol."},{"key":"88043_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fphar.2020.00117","volume":"11","author":"P Gisondi","year":"2020","unstructured":"Gisondi, P., Bellinato, F., Girolomoni, G. & Albanesi, C. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front. Pharmacol. 11, 12 (2020).","journal-title":"Front. Pharmacol."},{"key":"88043_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1146\/annurev-pathol-011811-132448","volume":"7","author":"GK Perera","year":"2012","unstructured":"Perera, G. K., Di Meglio, P. & Nestle, F. O. Psoriasis. Annu. Rev. Pathol. Mech. Dis. 7, 385\u2013422 (2012).","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"88043_CR17","first-page":"38","volume":"84","author":"D Engler","year":"2017","unstructured":"Engler, D., Chezuba, H. P. & Masuku, P. Psoriasis. SA Pharm. J. 84, 38\u201342 (2017).","journal-title":"SA Pharm. J."},{"key":"88043_CR18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"PO Frank Nestle","year":"2009","unstructured":"Frank Nestle, P. O., Kaplan, D. H. & Barker, J. Psoriasis. N. Engl. J. Med. 361, 496\u2013505 (2009).","journal-title":"N. Engl. J. Med."},{"key":"88043_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3109\/14397595.2016.1174328","volume":"27","author":"S Muramatsu","year":"2017","unstructured":"Muramatsu, S., Kubo, R., Nishida, E. & Morita, A. Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis. Mod. Rheumatol. 27, 137\u2013141 (2017).","journal-title":"Mod. Rheumatol."},{"key":"88043_CR20","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.18632\/oncotarget.22260","volume":"9","author":"F Bai","year":"2018","unstructured":"Bai, F. et al. Serum levels of adipokines and cytokines in psoriasis patients: A systematic review and meta-analysis. Oncotarget 9, 1266\u20131278 (2018).","journal-title":"Oncotarget"},{"key":"88043_CR21","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1002\/hep.22848","volume":"49","author":"L Miele","year":"2009","unstructured":"Miele, L. et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49, 1877\u20131887 (2009).","journal-title":"Hepatology"},{"key":"88043_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10809","volume":"482","author":"J Henao-Mejia","year":"2012","unstructured":"Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179\u2013185 (2012).","journal-title":"Nature"},{"key":"88043_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/MEG.0b013e32832fcdf0","volume":"22","author":"L Caballer\u00eda","year":"2010","unstructured":"Caballer\u00eda, L. et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur. J. Gastroenterol. Hepatol. 22, 24\u201332 (2010).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"88043_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/apt.13042","volume":"41","author":"KK Roberts","year":"2015","unstructured":"Roberts, K. K. et al. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Aliment. Pharmacol. Ther. 41, 293\u2013300 (2015).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"88043_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/ajd.13175","volume":"61","author":"J Magdaleno-Tapial","year":"2020","unstructured":"Magdaleno-Tapial, J. et al. Prevalence of non-alcoholic fatty liver and liver fibrosis in patients with moderate-severe psoriasis: A cross-sectional cohort study. Australas. J. Dermatol. 61, 105\u2013109 (2020).","journal-title":"Australas. J. Dermatol."},{"key":"88043_CR26","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1097\/MEG.0b013e328355b87f","volume":"24","author":"L Caballer\u00eda","year":"2012","unstructured":"Caballer\u00eda, L. et al. Metabolic syndrome and nonalcoholic fatty liver disease in a Spanish population: Influence of the diagnostic criteria used. Eur. J. Gastroenterol. Hepatol. 24, 1007\u20131011 (2012).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"88043_CR27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.medcli.2012.11.034","volume":"141","author":"L Caballer\u00eda","year":"2013","unstructured":"Caballer\u00eda, L. et al. Factores de riesgo asociados a la presencia de h\u00edgado graso no alcoh\u00f3lico: Un estudio de casos y controles. Med. Clin. 141, 233\u2013239 (2013).","journal-title":"Med. Clin."},{"key":"88043_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73\u201384 (2016).","journal-title":"Hepatology"},{"key":"88043_CR29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/archdermatol.2010.370","volume":"147","author":"TJ Love","year":"2011","unstructured":"Love, T. J., Qureshi, A. A., Karlson, E. W., Gelfand, J. M. & Choi, H. K. Prevalence of the metabolic syndrome in psoriasis: Results from the national health and nutrition examination survey, 2003\u20132006. Arch. Dermatol. 147, 419\u2013424 (2011).","journal-title":"Arch. Dermatol."},{"key":"88043_CR30","first-page":"132","volume":"22","author":"AN Ramos","year":"2014","unstructured":"Ramos, A. N., de OliveiraRocha, B., de AlmeidaR\u00eago, V. R. & de Follador, O. M. The linkage between psoriasis and non-alcoholic fatty liver disease: a literature review: PubMed. Acta Dermatovenerol. Croat 22, 132\u2013136 (2014).","journal-title":"Acta Dermatovenerol. Croat"},{"key":"88043_CR31","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jhep.2009.06.008","volume":"51","author":"L Miele","year":"2009","unstructured":"Miele, L. et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J. Hepatol. 51, 778\u2013786 (2009).","journal-title":"J. Hepatol."},{"key":"88043_CR32","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/ijd.14349","volume":"58","author":"L Chularojanamontri","year":"2019","unstructured":"Chularojanamontri, L., Silpa-archa, N., Wongpraparut, C. & Limphoka, P. Long-term safety and drug survival of acitretin in psoriasis: a retrospective observational study. Int. J. Dermatol. 58, 593\u2013599 (2019).","journal-title":"Int. J. Dermatol."},{"key":"88043_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/7963972","volume":"2016","author":"J Pongpit","year":"2016","unstructured":"Pongpit, J. et al. Liver stiffness measurement in psoriasis: Do metabolic or disease factors play the important role?. Biomed Res. Int. 2016, 1\u20136 (2016).","journal-title":"Biomed Res. Int."},{"key":"88043_CR34","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ad.2016.12.017","volume":"108","author":"JM Carrascosa","year":"2017","unstructured":"Carrascosa, J. M., Bonanad, C., Dauden, E., Botella, R. & Olveira-Mart\u00edn, A. Psoriasis and nonalcoholic fatty liver disease. Actas Dermo-Sifiliograficas 108, 506\u2013514 (2017).","journal-title":"Actas Dermo-Sifiliograficas"},{"key":"88043_CR35","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jhep.2007.01.024","volume":"46","author":"P Rosenberg","year":"2007","unstructured":"Rosenberg, P. et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J. Hepatol. 46, 1111\u20131118 (2007).","journal-title":"J. Hepatol."},{"key":"88043_CR36","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/art.1780360307","volume":"36","author":"AM Walker","year":"1993","unstructured":"Walker, A. M. et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum. 36, 329\u2013335 (1993).","journal-title":"Arthritis Rheum."},{"key":"88043_CR37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.15171\/jcvtr.2017.14","volume":"9","author":"LR Cuenza","year":"2017","unstructured":"Cuenza, L. R., Razon, T. L. J. & Dayrit, J. C. Correlation between severity of ultrasonographic nonalcoholic fatty liver disease and cardiometabolic risk among Filipino wellness patients. J. Cardiovasc. Thorac. Res. 9, 85\u201389 (2017).","journal-title":"J. Cardiovasc. Thorac. Res."},{"key":"88043_CR38","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1365-2249.2007.03494.x","volume":"150","author":"R Franc\u00e9s","year":"2007","unstructured":"Franc\u00e9s, R. et al. Translocation of bacterial DNA from Gram-positive microorganisms is associated with a species-specific inflammatory response in serum and ascitic fluid of patients with cirrhosis. Clin. Exp. Immunol. 150, 230\u2013237 (2007).","journal-title":"Clin. Exp. Immunol."},{"key":"88043_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/liv.12021","volume":"33","author":"P Bellot","year":"2013","unstructured":"Bellot, P., Franc\u00e9s, R. & Such, J. Pathological bacterial translocation in cirrhosis: Pathophysiology, diagnosis and clinical implications. Liver Int. 33, 31\u201339 (2013).","journal-title":"Liver Int."},{"key":"88043_CR40","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/ajg.2016.8","volume":"111","author":"A Guti\u00e9rrez","year":"2016","unstructured":"Guti\u00e9rrez, A. et al. Gut bacterial DNA translocation is an independent risk factor of flare at short term in patients with crohn\u2019s disease. Am. J. Gastroenterol. 111, 529\u2013540 (2016).","journal-title":"Am. J. Gastroenterol."},{"key":"88043_CR41","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/ibd.21537","volume":"17","author":"A Guti\u00e9rrez","year":"2011","unstructured":"Guti\u00e9rrez, A. et al. Antimicrobial peptide response to blood translocation of bacterial DNA in Crohn\u2019s disease is affected by NOD2\/CARD15 genotype. Inflamm. Bowel Dis. 17, 1641\u20131650 (2011).","journal-title":"Inflamm. Bowel Dis."},{"key":"88043_CR42","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/ibd.20806","volume":"15","author":"A Guti\u00e9rrez","year":"2009","unstructured":"Guti\u00e9rrez, A. et al. Cytokine association with bacterial DNA in serum of patients with inflammatory bowel disease. Inflamm. Bowel Dis. 15, 508\u2013514 (2009).","journal-title":"Inflamm. Bowel Dis."},{"key":"88043_CR43","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/liv.13551","volume":"38","author":"I G\u00f3mez-Hurtado","year":"2018","unstructured":"G\u00f3mez-Hurtado, I. et al. Norfloxacin is more effective than Rifaximin in avoiding bacterial translocation in an animal model of cirrhosis. Liver Int. 38, 295\u2013302 (2018).","journal-title":"Liver Int."},{"key":"88043_CR44","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1136\/gutjnl-2012-303557","volume":"63","author":"A Guti\u00e9rrez","year":"2014","unstructured":"Guti\u00e9rrez, A. et al. Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn\u2019s disease. Gut 63, 272\u2013280 (2014).","journal-title":"Gut"},{"key":"88043_CR45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00403-019-01965-2","volume":"312","author":"P Hisp\u00e1n","year":"2020","unstructured":"Hisp\u00e1n, P. et al. Identification of bacterial DNA in the peripheral blood of patients with active hidradenitis suppurativa. Arch. Dermatol. Res. 312, 159\u2013163 (2020).","journal-title":"Arch. Dermatol. Res."},{"key":"88043_CR46","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/jamadermatol.2014.5585","volume":"151","author":"A Ram\u00edrez-Bosc\u00e1","year":"2015","unstructured":"Ram\u00edrez-Bosc\u00e1, A. et al. Identification of bacterial DNA in the peripheral blood of patientswith active psoriasis. JAMA Dermatol. 151, 670\u2013671 (2015).","journal-title":"JAMA Dermatol."},{"key":"88043_CR47","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1053\/gast.2001.25540","volume":"121","author":"JB Dixon","year":"2001","unstructured":"Dixon, J. B., Bhathal, P. S. & O\u2019Brien, P. E. Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121, 91\u2013100 (2001).","journal-title":"Gastroenterology"},{"key":"88043_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jdv.13542","volume":"30","author":"E Daud\u00e9n","year":"2016","unstructured":"Daud\u00e9n, E., Puig, L., Ferr\u00e1ndiz, C., S\u00e1nchez-Carazo, J. L. & Hernanz-Hermosa, J. M. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. J. Eur. Acad. Dermatol. Venereol. 30, 1\u201318 (2016).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"88043_CR49","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","author":"JI Cleeman","year":"2001","unstructured":"Cleeman, J. I. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). J. Am. Med. Assoc. 285, 2486\u20132497 (2001).","journal-title":"J. Am. Med. Assoc."},{"key":"88043_CR50","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"JH Lee","year":"2010","unstructured":"Lee, J. H. et al. Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease. Dig. Liver Dis. 42, 503\u2013508 (2010).","journal-title":"Dig. Liver Dis."},{"key":"88043_CR51","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1053\/jhep.2002.33715","volume":"36","author":"J Such","year":"2002","unstructured":"Such, J. et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 36, 135\u2013141 (2002).","journal-title":"Hepatology"},{"key":"88043_CR52","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jhep.2009.09.001","volume":"51","author":"S Dasarathy","year":"2009","unstructured":"Dasarathy, S. et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: A prospective study. J. Hepatol. 51, 1061\u20131067 (2009).","journal-title":"J. Hepatol."},{"key":"88043_CR53","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/hep.30842","volume":"70","author":"QM Anstee","year":"2019","unstructured":"Anstee, Q. M. et al. Noninvasive tests accurately identify advanced fibrosis due to NASH: Baseline data from the STELLAR trials. Hepatology 70, 1521\u20131530 (2019).","journal-title":"Hepatology"},{"key":"88043_CR54","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321 (2005).","journal-title":"Hepatology"},{"key":"88043_CR55","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1053\/j.gastro.2014.07.056","volume":"147","author":"MM Yeh","year":"2014","unstructured":"Yeh, M. M. & Brunt, E. M. Pathological features of fatty liver disease. Gastroenterology 147, 754\u2013764 (2014).","journal-title":"Gastroenterology"},{"key":"88043_CR56","unstructured":"AHRQ. Quality Indicators. Prevention Quality Indicators Technical Specifications Updates\u2014Version 6.0 (ICD-9). https:\/\/www.qualityindicators.ahrq.gov\/Archive\/PQI_TechSpec_ICD09_v60.aspx (2016)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88043-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88043-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88043-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T12:09:40Z","timestamp":1675166980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88043-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,21]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["88043"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-88043-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,21]]},"assertion":[{"value":"17 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.B.R. acted as a consultant and\/or speaker for and\/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including Janssen Pharmaceuticals Inc, Almirall SA, Lilly, AbbVie, Novartis, Celgene, Biogen Amgen, Leo-Pharma, Pfizer-Wyeth, MSD, and UCB. The rest of the authors state do not declare conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8593"}}